NewAmsterdam Pharma Company N.V. Ordinary Shares
Follow $NAMS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NAMS by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is NAMS moving today?
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
NAMS overview
Related filings and maps
Congress activity in NAMS
No receipt-qualified Congressional disclosure is present for NAMS in the cached public ledger.
NAMS contract awards, year to date.
Public federal awards linked to this ticker.
NAMS lobbying filings, year to date.
Registered lobbying filings matched to NewAmsterdam Pharma Company N.V. Ordinary Shares.